Why the study?
What is the status of antithrombotic therapy prior to the onset of cardioembolic stroke in patients with non-valvular atrial fibrillation?
Observational (n=88)
No
What is the status of antithrombotic therapy prior to the onset of cardioembolic stroke in patients with non-valvular atrial fibrillation?
Antithrombotic therapy in NVAF patients who develop cardioembolic stroke is often insufficient, highlighting the need for more aggressive anticoagulation even in paroxysmal AF and CHADS2 score 1 patients.
Inadequate pre-stroke anticoagulation is common in NVAF cardioembolic stroke; leaves open whether broader use prevents events in lower-risk patients.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Taguchi et al. (2011) conducted an observational in Cardioembolic stroke due to non-valvular atrial fibrillation (n=88). Pre-admission oral warfarin therapy vs. No oral warfarin therapy was evaluated on Pre-admission oral warfarin therapy rate.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: